)
)
Hamlet BioPharma Investor Relations Material
Latest events
Investor Update
Hamlet BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Hamlet BioPharma
Access all reports
Hamlet Pharma AB, a pharmaceutical company, engages in the research and development of cancer drugs. The company's lead product candidate is a patented drug that combines the active ingredient Bisantrene-Guanidinylpenicillamine in a galenic form suitable for oral administration. Its BAR treatment is administered through small pills that slowly release the active ingredient into the upper part of the gastrointestinal tract. The company is headquartered in Malmö, Sweden.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
HAMLET
Country
🇸🇪 Sweden